IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Patent Information
- Application Number
- DE602023018930
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-07-01
- Filing Date
- 2023-06-29
- Publication Date
- 2026-06-24
- Estimated Expiration
- 2043-06-29
AI Technical Summary
There is a high unmet medical need for effective therapies targeting inflammatory, allergic, and autoimmune diseases, as well as cancers and metabolic disorders, where existing treatments are inadequate or have limited efficacy.
Development of novel imidazo[4,5-c]pyridine derivatives that act as selective inhibitors of Salt-inducible kinases (SIKs), particularly SIK2 and SIK3, to modulate macrophage polarization and reduce pro-inflammatory cytokines, promoting a pro-resolution phenotype and increasing anti-inflammatory IL-10 levels.
The compounds effectively reduce inflammation and promote tissue healing by enhancing IL-10 production and decreasing TNF-α and IL-6 levels, offering potential therapeutic benefits for conditions like rheumatoid arthritis and inflammatory bowel disease.